Reported results
- Research and Development (R&D) expenses were $34.1 million for the three months ended September 30, 2026.
- General and Administrative (G&A) expenses were $10.0 million for the three months ended September 30, 2026.
- Net loss was $39.0 million for the three months ended September 30, 2026.
- Net loss per share attributable to common stockholders, basic and diluted was $(0.22) for the three months ended September 30, 2026.
- The company raised $143.7 million in gross proceeds from an underwritten public offering in November 2026.
Guidance
- Prime Medicine expects that its cash, cash equivalents and investments as of September 30, 2026, together with net proceeds from its follow-on public offering of $134.7 million in November 2026, will be sufficient to fund its operating expenses and capital expenditure requirements through 2027.
Price and volatility reaction
The stock moved +9.8% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 3.89 | 2026-11-12 |
| Close after release | 4.27 | 2026-11-13 |
| Realised move | +9.8% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
